25/10/2010
Afghanistan
New bivalent polio vaccine playing key role in global polio eradication
Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial
A head to head trial against current poliovirus vaccines has found that the new bivalent oral vaccine against poliovirus, which targets both the remaining types of poliovirus concurrently, induces a stronger immune response than the traditional trivalent vaccine and a similar immune response to the latest monovalent (monovalent type 1 or monovalent type 3) vaccines. Furthermore, it is easier to administer, allowing children to be immunised against the two remaining types of wild poliovirus in a single oral dose. These are the conclusions of an Article published Online First in The Lancet.
For details, please go to:
http://www.thelancet.com
Related News
04/04/2024
As of January 2024, Iraq has achieved the polio transition process in full. It is the first country among the polio transition priority countries to achieve this remarkable feat.
27/03/2024
Interviews with four experts
11/03/2024
Women play central, diverse and multifaceted roles in safeguarding children from polio, proving that investments in women’s capacities and skills translate into investments in strengthening health systems.
